In a nutshell This study aimed to investigate the use of pembrolizumab (Keytruda) for prostate cancer (PCa). This study found that pembrolizumab was associated with a decline in prostate-specific antigen (PSA; a tumor marker for PCa). Some background Pembrolizumab is a type of immunotherapy. It works by triggering your...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as prostate cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...
Read MoreIn a nutshell This phase 2 trial is examining the effectiveness and safety of trametinib (Mekinist) in patients with metastatic castration-resistant prostate cancer (mCRPC; prostate cancer which has spread from its original place to another area in the body and keeps growing even when the amount of testosterone in the body...
Read More
In a nutshell This study evaluated how well palbociclib (Ibrance) works in patients with breast cancer who received multiple lines of previous therapy. This study found that palbociclib was effective for these patients. Some background There are several different treatments for breast cancer depending on the types of...
Read More
In a nutshell This study investigated the effectiveness of a radionuclide (RN), [¹??Lu]-PSMA-617, to treat metastatic castration-resistant prostate cancer (mCRPC) that has worsened after standard treatments. They found that this treatment was safe and effective for these patients. Some background Prostate cancer (PC) affects the...
Read More
In a nutshell This study aimed to investigate the link between PSA (prostate-specific antigen) levels and prostate cancer (PCa) prognosis. This study found that a lower PSA level (less than 0.2ng/ml) was associated with less risk of dying from PCa. Some background The PSA is a substance produced by the prostate. It can be used as a marker during...
Read More
In a nutshell This study looked at the effect of curcumin on prostate cancer. It concluded that curcumin taken for 6 months was safe but did not reduce the need for hormone suppression therapy. Some background Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate cancer can be treated by medication,...
Read More
In a nutshell This study aimed to evaluate the use of abiraterone (Zytiga) and olaparib (Lynparza) in advanced prostate cancer. This study concluded that olaparib in combination with abiraterone provided clinical benefit for patients with metastatic castration-resistant prostate cancer compared with abiraterone alone. Some background...
Read More
In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...
Read MoreIn a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...
Read MoreIn a nutshell This study aimed to investigate treatments given after chemotherapy and hormonal therapy for metastatic prostate cancer, resistant to castration. This study found some benefit in abiraterone (Zytiga) or enzalutamide (Xtandi) but not in using docetaxel (Taxotere) again. Some background Androgen deprivation therapy...
Read More
In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...
Read More
